Biotechnology · NASDAQ
Current Price
$313.41
Intrinsic Value
Use the calculator below to estimate
Run a PE ratio stock valuation on Alnylam Pharmaceuticals, Inc. with auto-filled earnings data, adjustable target PE, and instant fair value estimate.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Earnings Yield
0.76%
ROE (TTM)
90.3%
Based on trailing twelve-month data, ALNY has earnings per share of N/A and trades at a PE ratio of N/A. These are key inputs for stock valuation using the PE ratio method.
The trailing twelve-month PE ratio of ALNY is available in the calculator. This stock valuation metric shows how much investors pay per dollar of Alnylam Pharmaceuticals, Inc.'s earnings. Use MiniValuator's PE ratio calculator for detailed analysis.
Whether ALNY is overvalued depends on comparing its PE ratio to industry peers, historical averages, and growth expectations. A PE ratio above the sector average may indicate overvaluation, but high-growth companies often justify higher PE ratios. Run a full stock valuation on MiniValuator to analyze.
To value ALNY using PE ratio: compare its current PE to the sector average, analyze the PEG ratio for growth-adjusted stock valuation, check historical PE ranges, and estimate fair value by multiplying target PE by EPS. MiniValuator's PE ratio calculator automates this analysis.
The PEG ratio of ALNY is available in the calculator. PEG ratio divides the PE ratio by the earnings growth rate — a PEG below 1.0 may suggest the stock is undervalued relative to its growth, making it a useful complementary stock valuation metric.
PE ratio provides quick relative stock valuation — how ALNY compares to peers. DCF provides absolute stock valuation — what the stock is worth based on projected cash flows. For comprehensive stock valuation, use both methods together. MiniValuator offers both PE and DCF calculators.
